About Us:

Zebra Biologics Inc. is a pre-clinical stage biopharmaceutical  company pioneering  a "next-gen" approach to more efficiently and more effectively discovering and developing novel human biologic drugs utilizing proprietary platform technologies.


Zebra was conceived to exploit a technology recently developed at the Scripps Research Institute, San Diego that represents a quantum leap towards unlocking the utility and immense diversity of combinatorial antibody and peptide libraries as sources for deriving new drugs for both new and previously hard to drug targets.  The technology is applicable to virtually all disease areas.
  A unique feature of the Zebra platform is the ability to select agonist antibodies to any therapeutic target cell surface receptor using a novel functioned-based screening approach that employs a Zebra generated tailor-made reporter cell line for the target receptor.